NCT03532711
Completed
Not Applicable
A Study to Characterize and Evaluate Biomarkers of Chemotherapy in Patients With Metastatic Colorectal Cancer In The First-line Setting
Interventionsfluorouracil
Drugsfluorouracil
Overview
- Phase
- Not Applicable
- Intervention
- fluorouracil
- Conditions
- Metastatic Colorectal Cancer
- Sponsor
- Fudan University
- Enrollment
- 264
- Primary Endpoint
- Objective Response Rate (ORR)
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers. It may also help doctors predict how patients will respond to treatment. In this study, we aimed to evaluate biomarkers in chemotherapy regimens for first-line chemotherapy for mCRC.
Investigators
Wen Zhang
Dr
Fudan University
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Chemotherapy
FOLFOX/XELOX/FOLFIRI
Intervention: fluorouracil
Outcomes
Primary Outcomes
Objective Response Rate (ORR)
Time Frame: 2 months
objective response rate
Secondary Outcomes
- Overall Survival (OS)(6 months)
- Progression Free Survival (PFS)(6 months)
Similar Trials
Completed
Phase 1
Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before ProstatectomyProstate CancerNCT02324998Cambridge University Hospitals NHS Foundation Trust20
Unknown
Phase 2
XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal CancerColorectal NeoplasmsChemotherapyNCT03511170Harbin Medical University66
Unknown
Phase 2
XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal CancerColorectal NeoplasmsChemotherapyNCT03511183Harbin Medical University66
Unknown
Not Applicable
Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella TheoryColorectal Cancer MetastaticNCT04525807Fudan University200
Recruiting
Phase 1/2
Multicentric randomized phase I / II study to evaluate efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α True Human antibody) versus trifluridine/tipiracil +/- bevacizumab plus placebo in metastatic colorectal cancer patients after failure of oxaliplatin, irinotecan, fluoropyrimidine2024-517024-20-00Centr Georges Francois Leclerc190